Introduction: Measles is a viral disease that is a major public health problem in both developed and developing countries. It is a contagious disease resulting from infection with the measles virus and is still respon...Introduction: Measles is a viral disease that is a major public health problem in both developed and developing countries. It is a contagious disease resulting from infection with the measles virus and is still responsible for more than 100,000 deaths per year. Although vaccination is one of the most successful and cost-effective public health interventions to reduce mortality and morbidity, approximately 1.4 million children worldwide die from vaccine-preventable diseases each year. In Zambia, MCV2 was 66% below WHO recommended target of 95%. This study therefore assessed the acceptability of second dose measles vaccination services among caretakers/mothers with children less than two years of age in Livingstone, Zambia. Methods: The study used analytical cross-sectional study design. A logistic regression analysis was performed to identify factors associated with acceptability of the second dose of measles vaccine. A semi structured questionnaire was administered to collect data on socio demographic characteristics and factors related to acceptability of the second dose of measles vaccine. SPSS version 26.0 was used for descriptive and inferential analysis at 5% level of significance. Results: There was no statistically significant difference in acceptability of the second dose of measles vaccine by gender, marital status, type of employment, income level, socio-cultural and traditional beliefs, and education level. However, there was a statistically significant difference in acceptability of the second dose of measles vaccine by knowledge level of second dose of measles vaccine. A Chi square test result indicated that second dose acceptability was higher with less children than that of respondents with many children (χ2(5) = 15.3, p and knowledge levels (χ2(2) = 14.8, p Changes in knowledge level from medium to high reduced the odds of second dose measles vaccine acceptability. Furthermore, this study showed that acceptance of the second measles vaccination increased from mothers/caretakers with low knowledge (3.6%) to medium knowledge (13.3%) and finally high knowledge (83.1%). Conclusion: Tailored messaging to increase knowledge among mothers and caregivers on the importance of the second dose of measles vaccine is critical in improving acceptability. Therefore, the researchers recommend that the health providers should continue to raise awareness associated with the low acceptability of the second dose of measles vaccine and improve on child preventable diseases such as measles.展开更多
Objective:Capecitabine combined with docetaxel have demonstrated antitumor synergy for non-small cell lung cancer (NSCLC). Due to absence of phase I trial in China, we conducted this study to define the maximum-tolera...Objective:Capecitabine combined with docetaxel have demonstrated antitumor synergy for non-small cell lung cancer (NSCLC). Due to absence of phase I trial in China, we conducted this study to define the maximum-tolerated dose (MTD) of capecitabine with fixed docetaxel for Chinese patients with previously treated NSCLC. Methods:Previously treated patients with NSCLC were entered into this study. Escalating doses of capecitabine with fixed docetaxel were administered in a modified Fibonacci sequence. The initial doses were capecitabine 625 mg/m2, bid, on days d5-d18, and docetaxel 30 mg/m2 on days 1 and 8, respectively. The regimen was repeated every 21 days. If no dose-limiting toxicity (DLT) was observed, the next dose level was applied. The procedures were repeated until DLT appeared. The MTD was declared to be one dose level below the level at which DLT appeared. Results: Eighteen patients received 67 cycles at capecitabine of level I (1250 mg/m2, divided into 625 mg/m2, bid) and level II (1500 mg/m2, 750 mg/m2, bid). The most common toxicities were neutropenia, hand and feet syndrome, fatigue and nausea. Eight DLTs occurred in 5 patients in the whole group, including 1 DLT in dose level I and 7 DLTs in dose level 2. Since 4 of 6 patients in level II experienced DLTs, we declared thus level I was MTD. Conclusion: MTD of our phase I trial was capecitabine of 1250 mg/m2/d combined with docetaxel of 30 mg/m2/wk. This combination regimen was well tolerated for previously treated patients with NSCLC. The efficacy of this schedule is currently being further evaluated in a prospective phase II trial.展开更多
文摘Introduction: Measles is a viral disease that is a major public health problem in both developed and developing countries. It is a contagious disease resulting from infection with the measles virus and is still responsible for more than 100,000 deaths per year. Although vaccination is one of the most successful and cost-effective public health interventions to reduce mortality and morbidity, approximately 1.4 million children worldwide die from vaccine-preventable diseases each year. In Zambia, MCV2 was 66% below WHO recommended target of 95%. This study therefore assessed the acceptability of second dose measles vaccination services among caretakers/mothers with children less than two years of age in Livingstone, Zambia. Methods: The study used analytical cross-sectional study design. A logistic regression analysis was performed to identify factors associated with acceptability of the second dose of measles vaccine. A semi structured questionnaire was administered to collect data on socio demographic characteristics and factors related to acceptability of the second dose of measles vaccine. SPSS version 26.0 was used for descriptive and inferential analysis at 5% level of significance. Results: There was no statistically significant difference in acceptability of the second dose of measles vaccine by gender, marital status, type of employment, income level, socio-cultural and traditional beliefs, and education level. However, there was a statistically significant difference in acceptability of the second dose of measles vaccine by knowledge level of second dose of measles vaccine. A Chi square test result indicated that second dose acceptability was higher with less children than that of respondents with many children (χ2(5) = 15.3, p and knowledge levels (χ2(2) = 14.8, p Changes in knowledge level from medium to high reduced the odds of second dose measles vaccine acceptability. Furthermore, this study showed that acceptance of the second measles vaccination increased from mothers/caretakers with low knowledge (3.6%) to medium knowledge (13.3%) and finally high knowledge (83.1%). Conclusion: Tailored messaging to increase knowledge among mothers and caregivers on the importance of the second dose of measles vaccine is critical in improving acceptability. Therefore, the researchers recommend that the health providers should continue to raise awareness associated with the low acceptability of the second dose of measles vaccine and improve on child preventable diseases such as measles.
基金Supported by a grant of Science and Technology Department of Hebei Province,China(No.072761711)
文摘Objective:Capecitabine combined with docetaxel have demonstrated antitumor synergy for non-small cell lung cancer (NSCLC). Due to absence of phase I trial in China, we conducted this study to define the maximum-tolerated dose (MTD) of capecitabine with fixed docetaxel for Chinese patients with previously treated NSCLC. Methods:Previously treated patients with NSCLC were entered into this study. Escalating doses of capecitabine with fixed docetaxel were administered in a modified Fibonacci sequence. The initial doses were capecitabine 625 mg/m2, bid, on days d5-d18, and docetaxel 30 mg/m2 on days 1 and 8, respectively. The regimen was repeated every 21 days. If no dose-limiting toxicity (DLT) was observed, the next dose level was applied. The procedures were repeated until DLT appeared. The MTD was declared to be one dose level below the level at which DLT appeared. Results: Eighteen patients received 67 cycles at capecitabine of level I (1250 mg/m2, divided into 625 mg/m2, bid) and level II (1500 mg/m2, 750 mg/m2, bid). The most common toxicities were neutropenia, hand and feet syndrome, fatigue and nausea. Eight DLTs occurred in 5 patients in the whole group, including 1 DLT in dose level I and 7 DLTs in dose level 2. Since 4 of 6 patients in level II experienced DLTs, we declared thus level I was MTD. Conclusion: MTD of our phase I trial was capecitabine of 1250 mg/m2/d combined with docetaxel of 30 mg/m2/wk. This combination regimen was well tolerated for previously treated patients with NSCLC. The efficacy of this schedule is currently being further evaluated in a prospective phase II trial.
